These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 30526213)

  • 1. Ascending single dose pharmacokinetics of cytisine in healthy adult smokers.
    Jeong SH; Sheridan J; Bullen C; Newcombe D; Walker N; Tingle M
    Xenobiotica; 2019 Nov; 49(11):1332-1337. PubMed ID: 30526213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma concentrations of cytisine, a commercially available plant-based alkaloid, in healthy adult smokers taking recommended doses for smoking cessation.
    Jeong SH; Sheridan J; Newcombe D; Tingle M
    Xenobiotica; 2018 Dec; 48(12):1245-1248. PubMed ID: 29168931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of cytisine, an α4 β2 nicotinic receptor partial agonist, in healthy smokers following a single dose.
    Jeong SH; Newcombe D; Sheridan J; Tingle M
    Drug Test Anal; 2015 Jun; 7(6):475-82. PubMed ID: 25231024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytisine for smoking cessation: a research agenda.
    Etter JF; Lukas RJ; Benowitz NL; West R; Dresler CM
    Drug Alcohol Depend; 2008 Jan; 92(1-3):3-8. PubMed ID: 17825502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Public Health Impact of FDA's Request for Additional Safety Data on Cytisine for Tobacco Cessation.
    Reddy KP; Paltiel AD; Freedberg KA; Rigotti NA
    JAMA Health Forum; 2024 Aug; 5(8):e242647. PubMed ID: 39177985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytisine versus nicotine for smoking cessation.
    Walker N; Howe C; Glover M; McRobbie H; Barnes J; Nosa V; Parag V; Bassett B; Bullen C
    N Engl J Med; 2014 Dec; 371(25):2353-62. PubMed ID: 25517706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mental health related adverse events of cytisine and varenicline in smokers with and without mental health disorders: Secondary analysis of a randomized controlled trial.
    Rubaiya Talukder S; Lappin J; Clare Boland V; Weaver N; McRobbie H; James Courtney R
    Addict Behav; 2024 Dec; 159():108148. PubMed ID: 39213816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An uncontrolled trial of cytisine (Tabex) for smoking cessation.
    Zatonski W; Cedzynska M; Tutka P; West R
    Tob Control; 2006 Dec; 15(6):481-4. PubMed ID: 17130378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytisine for nicotine addiction treatment: a review of pharmacology, therapeutics and an update of clinical trial evidence for smoking cessation.
    Tutka P; Vinnikov D; Courtney RJ; Benowitz NL
    Addiction; 2019 Nov; 114(11):1951-1969. PubMed ID: 31240783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytisine: State of the art in pharmacological activities and pharmacokinetics.
    Wang X; Yang J; Huang P; Wang D; Zhang Z; Zhou Z; Liang L; Yao R; Yang L
    Biomed Pharmacother; 2024 Feb; 171():116210. PubMed ID: 38271893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytisine for smoking cessation: a literature review and a meta-analysis.
    Etter JF
    Arch Intern Med; 2006 Aug 14-28; 166(15):1553-9. PubMed ID: 16908787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of noncontingent and self-administered cytisine on body weight and meal patterns in male Sprague-Dawley rats.
    Grebenstein PE; Harp JL; Rowland NE
    Pharmacol Biochem Behav; 2013 Sep; 110():192-200. PubMed ID: 23876236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytisine induced urticaria : a case report during a smoking cessation treatment.
    Campagnari S; Casari R; Zamboni L; Fusina F; Lugoboni F
    Acta Biomed; 2022 Jun; 93(S1):e2022073. PubMed ID: 35731167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nicotinic receptor partial agonists as novel compounds for the treatment of smoking cessation.
    Tutka P
    Expert Opin Investig Drugs; 2008 Oct; 17(10):1473-85. PubMed ID: 18808308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of body condition on serum concentrations of two teratogenic alkaloids (anagyrine and ammodendrine) from lupines (Lupinus species) that cause crooked calf disease.
    Lee ST; Panter KE; Pfister JA; Gardner DR; Welch KD
    J Anim Sci; 2008 Oct; 86(10):2771-8. PubMed ID: 18539842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytisine's potential to be used as a traditional healing method to help indigenous people stop smoking: a qualitative study with Māori.
    Thompson-Evans TP; Glover MP; Walker N
    Nicotine Tob Res; 2011 May; 13(5):353-60. PubMed ID: 21385905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of CyTisine for smoking cessation in a hOSPital context (CITOSP): study protocol for a prospective observational study.
    Torazzi A; Tedesco E; Ceccato S; Santin L; Campagnari S; Losso L; Toldo S; Casari R; Arzenton E; Marini P; Chiamulera C; Lugoboni F
    Front Public Health; 2024; 12():1350176. PubMed ID: 39403432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Safety of nicotine addiction treatment].
    Korzeniowska K; Cieślewicz A; Jabłecka A
    Przegl Lek; 2013; 70(10):839-41. PubMed ID: 24501808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple-dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy smokers.
    Faessel HM; Gibbs MA; Clark DJ; Rohrbacher K; Stolar M; Burstein AH
    J Clin Pharmacol; 2006 Dec; 46(12):1439-48. PubMed ID: 17101743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolerability, pharmacokinetics and concentration-dependent hemodynamic effects of oral CF101, an A3 adenosine receptor agonist, in healthy young men.
    van Troostenburg AR; Clark EV; Carey WD; Warrington SJ; Kerns WD; Cohn I; Silverman MH; Bar-Yehuda S; Fong KL; Fishman P
    Int J Clin Pharmacol Ther; 2004 Oct; 42(10):534-42. PubMed ID: 15516022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.